Evidence map›Paper›PMID 39148854›Full record

ArticlemedRxiv : the preprint server for health sciences2024

Linoleoyl-lysophosphatidylcholine suppresses immune-related adverse events due to immune checkpoint blockade.

Ian T Mathews, Priyanka Saminathan, Mir Henglin, Mingyue Liu, Namratha Nadig, Camille Fang, Kysha Mercader, Serena J Chee, Allison M Campbell, Abhijit A Patel and 23 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors.

Ian T MathewsLa Jolla Institute for Immunology, La Jolla, CA 92037.ORCID 0000-0003-4773-7985
Priyanka SaminathanLa Jolla Institute for Immunology, La Jolla, CA 92037.
Mir HenglinCedars Sinai Medical Center, Los Angeles CA 90048.
Mingyue LiuInstitute of Human Virology, University of Maryland, Baltimore, MD 21201.
Namratha NadigLa Jolla Institute for Immunology, La Jolla, CA 92037.
Camille FangLa Jolla Institute for Immunology, La Jolla, CA 92037.
Kysha MercaderDepartment of Medicine, University of California San Diego, La Jolla CA 92093.
Serena J CheeUniversity of Southampton, Southampton, United Kingdom.
Allison M CampbellYale School of Medicine, New Haven CT 06520.
Abhijit A PatelYale School of Medicine, New Haven CT 06520.
Saumya TiwariDepartment of Medicine, University of California San Diego, La Jolla CA 92093.
Jeramie D WatrousDepartment of Medicine, University of California San Diego, La Jolla CA 92093.
Karthik RameshDepartment of Medicine, University of California San Diego, La Jolla CA 92093.
Martina DickerLa Jolla Institute for Immunology, La Jolla, CA 92037.
Khoi DaoDepartment of Medicine, University of California San Diego, La Jolla CA 92093.
Melissa A MeyerLa Jolla Institute for Immunology, La Jolla, CA 92037.
Pekka JousilahtiDepartment of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.
Aki S HavulinnaDepartment of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.
Teemu NiiranenDepartment of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.
Veikko SalomaaDepartment of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland.
Leo A B JoostenDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
Mihai G NeteaDepartment of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands.
Pan ZhengInstitute of Human Virology, University of Maryland, Baltimore, MD 21201.
Mitchell KronenbergLa Jolla Institute for Immunology, La Jolla, CA 92037.
Sandip Pravin PatelDepartment of Medicine, University of California San Diego, La Jolla CA 92093.
J Silvio GutkindMoores Cancer Center, University of California San Diego, La Jolla CA 92037.
Christian OttensmeierLa Jolla Institute for Immunology, La Jolla, CA 92037.
Tao LongDepartment of Medicine, University of California San Diego, La Jolla CA 92093.
Susan M KaechSalk Institute for Biological Studies, La Jolla CA 92037.
Catherine C HedrickImmunology Center of Georgia and Georgia Cancer Center, Medical College of Georgia at Augusta University, Augusta, GA 30912.
Susan ChengCedars Sinai Medical Center, Los Angeles CA 90048.
Mohit JainDepartment of Medicine, University of California San Diego, La Jolla CA 92093.
Sonia SharmaLa Jolla Institute for Immunology, La Jolla, CA 92037.

Funding

Using polygenic scores to enhance both variant discovery, and understanding of functional consequences of genetic variation in IBD.P01DK046763 · NIDDK · CEDARS-SINAI MEDICAL CENTER · PI TARGAN, STEPHAN R. · 1992 to 2020
$31.1M
GRADUATE TRAINING IN CELLULAR &MOLECULAR PHARMACOLOGYT32GM007752 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER, HANDEL, TRACY M · 1985 to 2023
$13.5M
The Microvascular Aging and Eicosanoids - Women's Evaluation of Systemic Aging Tenacity (MAE-WEST) ("You are never too old to become younger!") Specialized Center for Research Excellence (SCORE)U54AG065141 · NIA · CEDARS-SINAI MEDICAL CENTER · PI BAIREY MERZ, CATHLEEN NOEL · 2020 to 2024
$8.7M
Stimulating Neo-Antigen Specific T Cell Responses in Head and Neck CancersU01DE028227 · NIDCR · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI GUTKIND, JORGE SILVIO, RAO, ANJANA · 2018 to 2022
$4.6M
Bioactive Metabolites Modulate Immune-Related Adverse Events in Cancer ImmunotherapyR01CA256133 · NCI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI DENNIS, EDWARD A, SHARMA, SONIA · 2021 to 2025
$3.5M
Lung Cancer Screening via Ultrasensitive and Cost-efficient Analysis of Tumor DNA Signatures in BloodU01CA233364 · NCI · YALE UNIVERSITY · PI PATEL, ABHIJIT, SKATES, STEVEN J · 2018 to 2022
$3.4M
Mapping the Plasma Exposome and its Association with Human Cardiovascular DiseaseR01ES027595 · NIEHS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JAIN, MOHIT · 2017 to 2021
$3.3M
RapidFire mass spectrometry systemS10OD020025 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JAIN, MOHIT · 2015 to 2015
$600k
Small Molecule Metabolites as Predictors and Mediators of Immune Checkpoint Inhibitor ResponseF31CA236405 · NCI · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI MATHEWS, IAN T. · 2019 to 2020
$68k
NCI NIH HHS F31 CA236405NCI NIH HHS R01 CA256133NCI NIH HHS U01 CA233364NIA NIH HHS U54 AG065141NIDCR NIH HHS U01 DE028227NIDDK NIH HHS P01 DK046763NIEHS NIH HHS R01 ES027595NIGMS NIH HHS T32 GM007752NIH HHS S10 OD020025
6 · The paper itself

Abstract

Immune related adverse events (irAEs) after immune checkpoint blockade (ICB) therapy occur in a significant proportion of cancer patients. To date, the circulating mediators of ICB-irAEs remain poorly understood. Using non-targeted mass spectrometry, here we identify the circulating bio-active lipid linoleoyl-lysophosphatidylcholine (LPC 18:2) as a modulator of ICB-irAEs. In three independent human studies of ICB treatment for solid tumor, loss of circulating LPC 18:2 preceded the development of severe irAEs across multiple organ systems. In both healthy humans and severe ICB-irAE patients, low LPC 18:2 was found to correlate with high blood neutrophilia. Reduced LPC 18:2 biosynthesis was confirmed in preclinical ICB-irAE models, and LPC 18:2 supplementation

Identifiers

PMID39148854
PMCPMC11326322

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.